Elevate your local knowledge
Sign up for the iNFOnews newsletter today!
NEW YORK, N.Y. – Pfizer’s second-quarter net income more than quadrupled, helped by the sale of its animal health business.
The drug company earned $14.1 billion, or $1.98 per share. That compares with $3.25 billion, or 43 cents per share, a year earlier.
Excluding a gain related to the sale of its remaining stake in Zoetis Inc. and other one-time items, earnings were 56 cents per share, a penny better than Wall Street had expected.
Revenue fell 7 per cent to $12.97 billion from $14 billion partly due to generic competition and the loss of exclusivity on Lipitor in Europe. That’s just short of the $13.21 billion analysts were expecting.
The New York company maintained its full-year adjusted earnings outlook of $2.10 to $2.20 per share. Analysts forecast $2.16 per share.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Want to share your thoughts, add context, or connect with others in your community?
You must be logged in to post a comment.